Contracts › 75A50324C00006
75A50324C00006: Anthim (Obiltoxaximab)
Awarded to Elusys Therapeutics Inc by Office of Assistant Secretary for Preparedness and Response.
$124.5Mobligated
$124.5Mpotential value
31 December 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50324C00006 |
|---|---|
| Awardee | Elusys Therapeutics Inc |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | ASPR/ORM-SNS |
| NAICS | 325412 Pharmaceutical Preparation Manufacturing |
| PSC | 6505 Drugs and Biologicals |
| Place of performance | NJ |
| Offers received | 1 |
| Period of performance | 01 May 2024 to 31 December 2028 |
| Potential end | 31 December 2028 |
| Estimated recompete solicitation | ~Q3 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 325412 contracts · All expiring contracts · USASpending record